Am J Transplant, Volume 22, Suppl 3 Archives - Page 175 of 190 - ATC Abstracts

2022 American Transplant Congress
Outcomes of Highly-Sensitized, Virtual and Flow Cross-Match Negative Renal Transplant Recipients: A Retrospective Observational Study
A. Agrawal¹, B. Smith¹, M. Gandhi², C. Schinstock¹
¹Transplant Nephrology, Mayo Clinic, Rochester, MN, ²Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
*Purpose: Many highly-sensitized kidney transplant recipients are sensitized from prior transplants, which have been shown to limit graft survival more than pregnancy or blood transfusions.…
2022 American Transplant Congress
Impact of Mycetoma in Lung Transplant Recipients
A. Majeed, S. Singh, J. Lum
CCF, Cleveland, OH
*Purpose: Mycetoma are uncommon in lung transplant recipients (LTRs) and previous studies describe poor outcomes. We reviewed our experience*Methods: Retrospective review of electronic medical records…
2022 American Transplant Congress
Biopsy and Blood Gene Expression Profiles Distinguish Injury, Subclinical and Clinical Rejection in Kidney Transplant Recipients
S. Kurian¹, M. Kandpal², C. Rebello², C. Marsh¹, J. Friedewald²
¹Scripps Health, La Jolla, CA, ²Northwestern University, Chicago, IL
*Purpose: We analyzed serial gene expression profiles in paired blood and biopsies from kidney transplant recipients phenotyped with a comprehensive clinical algorithm. We compared disease…
2022 American Transplant Congress
Circulating Antibodies in CMV Viremia in Kidney Transplantation
T. Sigdel¹, P. Velpurisiva¹, V. Dharnidharka², M. M. Sarwal¹
¹UCSF, San Francisco, CA, ²Washington University in St. Louis, Saint Louis, MO
*Purpose: Role of circulating antibodies (Abs) in graft injury outcomes of kidney transplant is reported by us and others. Cytomegalovirus (CMV) is known to contribute…
2022 American Transplant Congress
Data-Driven Clustering Distinguishes Infection from Rejection During Hospital Admissions Following Pediatric Lung Transplantation
C. D. Britto¹, D. Boyer², G. Visner³, G. Priebe⁴, L. Midyat³
¹Department of Pediatrics, Boston Children's Hospital, Boston, MA, ²Division of Pulmonary Medicine, Nationwide Children's Hospital, Ohio, MA, ³Division of Pulmonary Medicine, Boston Children's Hospital, Boston, MA, ⁴Department of Anesthesiology, Critical Care and Pain Medicine, Division of Infectious Disease, Boston Children's Hospital, Boston, MA
*Purpose: When lung transplantation patients are admitted with respiratory symptoms, distinguishing between episodes of infection and rejection is central to determining immunosuppressive management.*Methods: Data comprising…
2022 American Transplant Congress
Effect of CD8+ Cell Depletion in Treg Mediated Skin Graft Survival
R. Steiner¹, A. M. Weijler¹, M. Muckenhuber², J. Sprent³, T. Wekerle⁴, N. Pilat¹
¹Medical University of Vienna, Vienna, Austria, ²Dept. of General Surgery, Div. of Transplantation, Medical University of Vienna, Vienna, Austria, ³Garvan Institute of Medical Research, Sydney, Australia, ⁴Vienna Gen Hosp / Medical Univ of Vienna, A-1090 Vienna, Austria
*Purpose: The selective in vivo expansion and activation of regulatory T cells via administration of interleukin-2 (IL-2) coupled to a specific antibody against IL-2 (IL-2…
2022 American Transplant Congress
Adenosine A2A Receptor (A2AR) Agonist Apadenoson Promotes Survival in K28-hACE2 Mice and Syrian Hamsters Infected with Sars-CoV-2
P. Chhabra¹, B. Mann², M. Ma¹, S. Feldman³, J. Linden⁴, K. L. Brayman¹
¹Department of Surgery, University of Virginia Health System, Charlottesville, VA, ²Department of Infectious Diseases, University of Virginia Health System, Charlottesville, VA, ³Center for Comparative Medicine, University of Virginia Health System, Charlottesville, VA, ⁴Department of Nephrology, University of Virginia Health System, Charlottesville, VA
*Purpose: To determine if Apadenoson or Regadenoson has a therapeutic effect in attenuating hyper-inflammation and improving survival rate in K18-hACE2mice or Syrian hamsters infected with…
2022 American Transplant Congress
Single Center Retrospective Study Examining the Incidence of Chronic Kidney Disease After Lung Transplantation and Its Associated Risk Factors
S. Kapoor¹, Y. Azzi¹, M. Ajaimy¹, P. Loarte-Campos¹, C. Pynadath¹, A. Mansour¹, E. Akalin², L. Liriano-Ward¹
¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, Montefiore Medical Ctr, Bronx, NY
*Purpose: To examine the incidence of chronic kidney disease (CKD) after lung transplantation and to evaluate the recipient-related risk factors associated with the development of…
2022 American Transplant Congress
Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety and Tolerability in a Phase 2 Trial
R. K. Wali¹, M. Singh², D. Wojciechowski³, M. J. Ansari⁴, B. Lonze⁵, V. Nair⁶, A. Sharma⁷, S. Knechtle⁸, F. Cardarelli⁹, A. Chandraker¹⁰
¹Inova Transplant Center, Falls Church, VA, ²U. of Pittsburg Medical Center, Harrisburg, PA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Northwestern U. Feinberg School of Medicine, Chicago, IL, ⁵NYU Langone Transplant Institute, New York, NY, ⁶Northwell Health, Manhasset, NY, ⁷U. of Pittsburgh Medical Center, Pittsburgh, PA, ⁸Duke U. School of Medicine, Durham, NC, ⁹AlloVir, Cambridge, MA, ¹⁰Brigham & Women's Hospital, Boston, MA
*Purpose: Kidney transplant (KT) recipients with BK viremia are at risk for BK virus (BKV) nephropathy and graft loss. There are no approved therapies for…
2022 American Transplant Congress
Pre-Transplant Desensitization Utilizing Intravenous Immune-Globulin and Tocilizumab: A Single Center Experience
I. Moinuddin, M. Miles, S. Sterling, A. Brown, P. Kimball, G. Gupta
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Highly sensitized end stage kidney disease patients face a huge barrier to transplant due to lack of effective pre-transplant desensitization therapies. Various strategies have…